10-Q: Cannabis Bioscience International Holdings Reports Increased Revenue but Continues to Face Going Concern Challenges

Cannabis Bioscience International Holdings reports increased revenue for the six months ended November 30, 2024, but continues to face challenges related to its going concern status.

Summary

• Cannabis Bioscience International Holdings, Inc. reported its financial results for the quarter and six months ended November 30, 2024.
• The company experienced an increase in revenue for both the three and six-month periods compared to the same periods in the previous year.
• Revenue for the three months ended November 30, 2024, was $74,248, compared to $63,748 in 2023, primarily due to increased clinical trial revenue.
• For the six months ended November 30, 2024, revenue was $253,135, up from $136,569 in 2023, driven by higher clinical trial and consulting fees.
• The company's operating loss decreased to $59,627 for the three months ended November 30, 2024, from $94,512 in 2023, and to $157,231 for the six months ended November 30, 2024, from $268,182 in 2023.
• Net loss for the three months ended November 30, 2024, was $79,528, compared to $124,428 in 2023, and for the six months ended November 30, 2024, was $155,833, compared to $306,217 in 2023.
• The company's cash and cash equivalents stood at $1,002 as of November 30, 2024, with a negative working capital of $857,255.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit of $5,489,913.
• The company is dependent on raising additional capital through debt or equity financing to fund its operations and repay debts.

Sentiment

Score: 3

Explanation: The document shows some positive trends in revenue growth and reduced losses, but the company's going concern status, negative working capital, and reliance on related party transactions create a negative sentiment overall. The company's financial position is precarious and requires significant improvement.

Positives

• The company experienced an increase in revenue for both the three and six-month periods.
• The company's operating loss decreased for both the three and six-month periods.
• The net loss decreased for both the three and six-month periods.
• The company recorded a gain of $23,638 from the forgiveness of debt.

Negatives

• The company continues to operate at a loss.
• The company has a negative working capital of $857,255.
• The company has an accumulated deficit of $5,489,913.
• The company's cash balance is very low at $1,002.
• The company has significant related party payables of $559,488.
• The company has a going concern issue due to recurring losses and negative cash flows.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
• The company is dependent on raising additional capital through debt or equity financing.
• There is no assurance that the company will be able to obtain additional financing on satisfactory terms or at all.
• The company's operations could be materially negatively impacted or terminated if adequate capital cannot be obtained.
• The company has significant debt obligations, including short-term loans and SBA loans.
• The company has a concentration of risk with a small number of customers providing a large portion of its revenue.

Future Outlook

The company's ability to continue as a going concern depends on the successful execution of its operating plan, increasing sales, introducing new products and services, and raising additional capital through debt or equity financing. There is no assurance that the company will be able to obtain such financing on satisfactory terms or at all.

Management Comments

• The company's management has evaluated the effectiveness of the design and operation of the company's disclosure controls and procedures.
• The principal executive officer and the principal accounting officer concluded that these disclosure controls and procedures were not effective as of November 30, 2024.
• Management has evaluated all subsequent events and determined that none of them requires disclosure.

Industry Context

The company operates in the medical cannabis and clinical trials sectors, which are both experiencing growth but also face regulatory and competitive challenges. The company's focus on education and clinical trials positions it to capitalize on the increasing acceptance of medical cannabis, but it must overcome its financial challenges to succeed.

Comparison to Industry Standards

• The company's revenue growth is positive compared to the previous year, but its overall financial position is weak compared to industry standards.
• Many companies in the cannabis sector are experiencing rapid growth, but also face challenges with profitability and cash flow.
• Companies like Canopy Growth and Aurora Cannabis have faced similar challenges with profitability and cash flow, but have significantly larger revenue bases.
• The company's negative working capital and accumulated deficit are concerning compared to industry benchmarks for companies of similar size and stage.
• The company's reliance on related party transactions and loans is also a risk factor compared to industry best practices.

Related Party Transactions

• The company has significant related party payables of $559,488 as of November 30, 2024.
• The company entered into a loan agreement with related parties for $75,000 on September 1, 2024.
• The company entered into a loan agreement with a related party for $50,000 on November 7, 2024.
• The company issued 250,000,000 shares of common stock to a related party for $75,000 on December 27, 2024.
• Two of the company's officers leased office space and made it available to the company for a monthly payment of $2,817.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern status and financial challenges.
• Employees may be impacted by potential layoffs or business termination if the company cannot secure additional funding.
• Customers may be affected by potential disruptions in services if the company's financial situation does not improve.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company needs to successfully execute its operating plan.
• The company needs to increase sales of existing services and introduce new products and services.
• The company needs to raise additional capital through debt or equity financing.
• The company needs to address its going concern issue.

Key Dates

Keywords

Cannabis Bioscience International Holdings, clinical trials, cannabinoids, revenue, operating loss, net loss, going concern, debt financing, equity financing, working capital, SBA loans, related party transactions